Edition:
United States

SMA Solar Technology AG (S92G.DE)

S92G.DE on Xetra

17.63EUR
7 Dec 2018
Change (% chg)

€-0.51 (-2.81%)
Prev Close
€18.14
Open
€18.33
Day's High
€18.47
Day's Low
€17.49
Volume
96,266
Avg. Vol
134,264
52-wk High
€63.15
52-wk Low
€16.99

Chart for

About

SMA Solar Technology AG is a Germany-based developer of photovoltaic (PV) system technology. The Company operates through five segments: Residential, Commercial, Utility, Off-Grid and Storage and Service. The Residential segment focuses on small PV systems for private applications with micro and string inverters, energy... (more)

Overall

Beta: 0.44
Market Cap(Mil.): €1,231.85
Shares Outstanding(Mil.): 34.70
Dividend: 0.26
Yield (%): 0.73

Financials

  S92G.DE Industry Sector
P/E (TTM): 64.12 14.53 1,221.35
EPS (TTM): 0.55 -- --
ROI: 2.18 14.97 14.00
ROE: 3.27 -6.21 14.15

SMA Solar CEO steps down, to be replaced by deputy

FRANKFURT, Oct 15 SMA Solar, Germany's largest solar group, on Monday named Juergen Reinert, deputy chief executive and board member for operations and technology, as its new CEO, replacing Pierre-Pascal Urbon, who is leaving after seven years at the helm.

Oct 15 2018

UPDATE 1-SMA Solar shares plunge to 1-yr low on China woes

* Shares fall to lowest level since late-July 2017 (Recasts, adds shares, context)

Aug 09 2018

SMA Solar expects chips shortage to ease in H2

FRANKFURT, Aug 9 SMA Solar, Germany's largest solar company, on Thursday said it expected a shortage of chips needed for the production of solar inverters to ease in the second half of the year, which the company said would lead to higher sales.

Aug 09 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

Jun 18 2018

Roche SMA drug shines in study as costly new therapies advance

ZURICH, June 18 A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.

Jun 18 2018

Earnings vs. Estimates